CHICAGO: Kyle S. Nicholson, GlobalData’s analyst covering neurology stated that although it is essential that larger and smaller players within the pharma industry collaborate to facilitate progress in Alzheimer’s and Parkinson’s drug development, public funding must be provided to reduce the risks involved from a business perspective.
He added: “One of the most problematic areas in the AD drug development process is phase II, where the level of research is associated with a needed investment of up to $25 million, and the success rate is as low as 25 per cent…